Novo Nordisk Partners with Vivani Medical on Long-Acting GLP-1 Implant Technology
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Novo Nordisk is partnering with Vivani Medical to develop a long-acting implantable delivery system for GLP-1 receptor agonists, aiming to reduce dosing frequency for patients.
- This collaboration leverages Novo Nordisk's established expertise in GLP-1 receptor agonist pharmacology, exemplified by semaglutide (Ozempic, Wegovy), with Vivani Medical's proprietary implant technology.
- The development targets overcoming the short pharmacokinetic half-lives inherent to peptide-based therapies, a common challenge necessitating frequent administration.
- Potential benefits of an implantable GLP-1 formulation include improved patient adherence and convenience compared to current weekly subcutaneous injections.
- This strategic move aligns with a broader pharmaceutical trend towards sustained-release formulations for peptide therapeutics to enhance therapeutic efficacy and patient compliance.
Novo Nordisk has entered into a deal with California-based medtech company Vivani Medical to develop long-acting implant technology for GLP-1 therapies. The Danish drugmaker is seeking new ways to expand its semaglutide GLP-1 franchise through this partnership.
The agreement combines Novo Nordisk's expertise in GLP-1 receptor agonists with Vivani Medical's implant delivery platform. The goal is to create a long-acting formulation that could reduce the frequency of dosing for patients. Specific financial terms, timelines, and development milestones were not disclosed in the announcement.
Context
GLP-1 receptor agonists are a class of drugs originally developed for type 2 diabetes that have gained widespread attention for their effectiveness in weight management. Semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is currently administered as a weekly injection. An implant-based delivery system could offer patients a longer-lasting alternative, potentially improving adherence and convenience. This deal reflects a broader industry trend toward developing sustained-release formulations for peptide-based therapies, which are typically limited by short half-lives and require frequent administration.
Source: original report